Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative …

Y Bashir, F Noor, S Ahmad, MH Tariq… - Journal of …, 2024 - Taylor & Francis
Triple negative breast cancers (TNBC) are clinically heterogeneous but mostly aggressive
malignancies devoid of expression of the estrogen, progesterone, and HER2 (ERBB2 or …
被引用次数：8 相关文章
[PDF] researchgate.net

[PDF][PDF] Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple …

Y Bashir, F Noor, S Ahmad, MH Tariq, M Qasim… - researchgate.net
Triple negative breast cancers (TNBC) are clinically heterogeneous but mostly aggressive
malignancies devoid of expression of the estrogen, progesterone, and HER2 (ERBB2 or …

Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative …

Y Bashir, F Noor, S Ahmad, MH Tariq… - … structure & dynamics - pubmed.ncbi.nlm.nih.gov
Triple negative breast cancers (TNBC) are clinically heterogeneous but mostly aggressive
malignancies devoid of expression of the estrogen, progesterone, and HER2 (ERBB2 or …

Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative …

Y Bashir, F Noor, S Ahmad, MH Tariq… - Journal of …, 2024 - ingentaconnect.com
Triple negative breast cancers (TNBC) are clinically heterogeneous but mostly aggressive
malignancies devoid of expression of the estrogen, progesterone, and HER2 (ERBB2 or …

Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative …

Y Bashir, F Noor, S Ahmad, MH Tariq… - … Structure & Dynamics, 2023 - europepmc.org
Triple negative breast cancers (TNBC) are clinically heterogeneous but mostly aggressive
malignancies devoid of expression of the estrogen, progesterone, and HER2 (ERBB2 or …